Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Live Cell Spectroscopy Analysis for Personalised Particle Radiation Therapy of Metastatic Bone Cancer

Project description

Improved monitoring of metastatic bone cancer treatment

Metastatic bone cancer is incurable and challenging to treat, something further complicated by the inability to monitor tumours during standard particle radiotherapy (PRT). Tumour imaging is currently done only at the beginning and end of PRT due to the high radiation dose required. Funded by the European Innovation Council, the BoneOscopy project aims to enable daily monitoring with accurate spectroscopic analysis of very small tumour volumes, detecting signals emitted from cancerous cells during PRT without additional radiation. Leveraging cutting-edge mathematical and software innovations, BoneOscopy will enable safe, personalised, quantitative analysis of treatment efficacy that has the potential to improve patient outcomes, reduce healthcare costs and make healthcare more sustainable.

Objective

Metastatic bone cancer is an incurable disease and one of the most complex cancers to treat. Due to the high dose, tumour imaging is currently performed at the beginning and end of standard particle radio-therapy (PRT), making personalised treatment difficult. The main goal of BoneOscopy is to develop a radically new technology to enable informed medical decisions by monitoring bone cancer on a daily basis during PRT. At the heart of BoneOscopy is the ability to detect prompt gamma (PGs) emitted by cancer during PRT and separate them from healthy tissue, unlocking the full potential of spectroscopic analysis without the need for additional dose. The development of a highly specialised detection and collimation system will enable accurate spectroscopic analysis of a very small volume or region within the cancer. As the number of PRT centres grows, we anticipate that within 10 years BoneOscopy will benefit all patients treated with proton and carbon ions. The objectives of BoneOscopy will be achieved by its interdisciplinary consortium, which brings together six partners from five European countries with key expertise in bioengineering and PRT (DKFZ), medical physics and engineering (CSIC), fast electronics for PRT (LIP), Monte Carlo simulations and clinical PRT experience (THM), turnkey software for high performance medical devices (Cosylab) and EU project management, communication and dissemination (accelCH). If achieved, the proposed science-to-technology breakthrough will have a transformative impact on current cancer treatment by providing a safe, personalised and quantitative measure of daily treatment efficacy, thereby contributing to the global fight against cancer. In summary, BoneOscopy will lead to a significant reduction in the health burden in Europe and worldwide, improved quality of life for patients, reduced costs for healthcare systems and improved sustainability of healthcare.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Coordinator

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Net EU contribution
€ 815 875,00
Address
IM NEUENHEIMER FELD 280
69120 Heidelberg
Germany

See on map

Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Research Organisations
Links
Total cost
€ 815 875,00

Participants (4)

Partners (1)